Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer

Praveen Kumar Marimuthu, DM Resident in Medical Oncology at Christian Medical College and Hospital, shared an article by Rebecca Kristeleit, et al. on X:

“Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer.

12-wk PFS: 42%.
ORR: 25%.
Median DOR: 13.1 mo.
Median OS: 14.8 mo.”

Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical Trial.

Journal: Jama Network

Authors: Rebecca Kristeleit, Michael-John Devlin, Andrew Clamp, Charlie Gourley, René Roux, Marcia Hall, Rachel Nirsimloo, Valentinos Kounnis, Lesley Sage, Priya Narayanan, C. Simon Herrington, Rupali Arora, Laura Farrelly, Laura Hughes, Nicholas Counsel, Rowan E. Miller, et al.

You can Read the Full Article on Journal of JAMA NETWORK.

Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer

More posts featuring Praveen Kumar Marimuthu.

Science

Advanced Clear Cell Gynecological Cancer Andrew Clamp C. Simon Herrington cancer Charlie Gourley Christian Medical College and Hospital clinical trial fight against cancer Global fight against cancer Gynecological Cancer JAMA Network Laura Farrelly Laura Hughes Lesley Sage Marcia Hall MedOnc Michael-John Devlin Nicholas Counsel OncoDaily Oncology pembrolizumab Praveen Kumar Marimuthu Priya Narayanan Rachel Nirsimloo Rebecca Kristeleit René Roux Rowan E. Miller Rupali Arora Valentinos Kounnis